Braveheart Bio (NASDAQ:BRVE) Major Shareholder Bio Fund Iv L.P. Ah Buys 1,100,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the transaction, the insider owned 10,232,420 shares in the company, valued at approximately $184,183,560. The trade was a 12.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Braveheart Bio Stock Down 9.2%

BRVE stock opened at $25.01 on Wednesday. Braveheart Bio, Inc. has a 52-week low of $24.61 and a 52-week high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.